Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 15 01:21PM ET
57.87
Dollar change
+0.28
Percentage change
0.49
%
IndexS&P 500 P/E- EPS (ttm)-6.36 Insider Own2.79% Shs Outstand180.00M Perf Week1.32%
Market Cap10.47B Forward P/E50.91 EPS next Y1.14 Insider Trans-0.09% Shs Float175.94M Perf Month3.42%
Income-1152.00M PEG- EPS next Q0.47 Inst Own94.83% Short Float4.89% Perf Quarter2.78%
Sales4.15B P/S2.52 EPS this Y-95.30% Inst Trans-7.71% Short Ratio5.05 Perf Half Y15.52%
Book/sh20.06 P/B2.88 EPS next Y2335.70% ROA-11.13% Short Interest8.61M Perf Year25.11%
Cash/sh0.90 P/C64.64 EPS next 5Y32.41% ROE-27.71% 52W Range31.80 - 60.20 Perf YTD28.79%
Dividend Est.- P/FCF- EPS past 5Y- ROI-13.48% 52W High-3.88% Beta1.16
Dividend TTM- Quick Ratio1.77 Sales past 5Y15.24% Gross Margin19.38% 52W Low81.96% ATR (14)0.58
Dividend Ex-Date- Current Ratio2.51 EPS Y/Y TTM-2835.82% Oper. Margin0.43% RSI (14)67.14 Volatility1.13% 0.91%
Employees17800 Debt/Eq1.38 Sales Y/Y TTM-8.25% Profit Margin-27.77% Recom2.90 Target Price63.43
Option/ShortYes / Yes LT Debt/Eq1.37 EPS Q/Q55.75% Payout- Rel Volume0.61 Prev Close57.58
Sales Surprise-4.32% EPS Surprise-127.86% Sales Q/Q3.57% EarningsMay 08 AMC Avg Volume1.71M Price57.87
SMA202.64% SMA503.72% SMA20015.02% Trades Volume633,424 Change0.49%
Date Action Analyst Rating Change Price Target Change
Nov-16-23Upgrade Robert W. Baird Neutral → Outperform $45 → $53
Sep-05-23Upgrade Argus Hold → Buy $62
Jul-20-23Initiated Wells Fargo Equal Weight $43
Jul-05-23Resumed JP Morgan Neutral $45
Jun-14-23Downgrade Jefferies Buy → Hold $45 → $44
May-22-23Downgrade JP Morgan Overweight → Neutral $90 → $45
May-15-23Downgrade Deutsche Bank Buy → Hold $55 → $29
May-08-23Downgrade BofA Securities Neutral → Underperform $28
Apr-17-23Downgrade Robert W. Baird Outperform → Neutral $82 → $53
Apr-14-23Downgrade William Blair Outperform → Mkt Perform
Jul-01-24 08:00AM
Jun-21-24 05:05PM
01:00PM
Jun-11-24 01:13PM
Jun-07-24 11:30AM
10:00AM Loading…
Jun-06-24 10:00AM
May-29-24 09:07AM
May-27-24 03:02AM
May-16-24 02:26PM
May-14-24 10:33AM
May-13-24 11:46AM
11:20AM
May-09-24 01:31PM
01:05AM
12:53AM
11:37PM Loading…
May-08-24 11:37PM
07:30PM
06:24PM
04:15PM
May-03-24 10:12AM
09:50AM
08:58AM
08:36AM
08:16AM
04:17AM
04:02AM
May-02-24 01:08PM
11:31AM
08:19AM
08:02AM
06:18AM Loading…
06:18AM
Apr-17-24 08:19PM
Apr-16-24 09:53AM
Apr-11-24 02:21AM
Apr-10-24 11:03PM
Apr-08-24 06:31AM
06:28AM
05:55AM
Apr-05-24 11:08PM
Mar-28-24 01:15PM
Mar-11-24 12:44PM
Mar-09-24 01:00PM
Mar-08-24 07:11AM
Mar-07-24 10:41AM
10:31AM
08:00AM
Feb-27-24 10:50AM
Feb-14-24 04:43PM
Feb-13-24 12:32AM
Feb-10-24 09:53AM
Feb-09-24 11:28AM
09:30AM
09:13AM
08:37AM
08:14AM
08:11AM
08:03AM
07:59AM
Feb-08-24 06:37AM
05:48AM
04:53AM
Feb-07-24 12:55PM
12:23PM
11:53AM
07:51AM
Feb-06-24 05:23PM
02:44PM
12:22PM
11:13AM
09:47AM
08:37AM
06:19AM
Feb-05-24 06:35PM
06:25PM
06:07PM
04:35PM
04:32PM
02:41PM
02:03PM
01:46PM
01:21PM
01:04PM
12:38PM
12:27PM
12:13PM
11:04AM
10:57AM
10:36AM
10:35AM
10:29AM
10:26AM
09:03AM
07:59AM
07:40AM
06:56AM
06:47AM
06:19AM
06:18AM
06:16AM
06:07AM
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Masanovich MattiSVP, Chief Financial OfficerJul 08 '24Sale56.742,993169,82333,871Jul 10 04:56 PM
Hopson RickyPres. BioProduct Delivery, CoSJun 04 '24Sale54.261,40176,02320,617Jun 05 09:35 PM
Gunther ScottSVP, Quality & Reg. AffairsMar 15 '24Sale56.2038721,74929,506Mar 19 01:38 PM
Ryan Michelle RDirectorAug 31 '23Buy49.981,00049,9801,979Sep 05 06:00 PM
GREISCH JOHN JExecutive ChairAug 30 '23Buy50.2421,0001,055,04034,000Sep 01 01:52 PM
Maselli AlessandroPresident & CEOAug 24 '23Sale44.542,07192,24588,004Aug 25 07:16 PM
Fasman Steven LEVP & Chief Admin OfficerAug 24 '23Sale44.6581736,47973,789Aug 25 07:02 PM
Gennadios AristipposGroup Pres. Pharma & ConsumerAug 24 '23Sale44.4939617,61896,552Aug 25 07:05 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Aug 24 '23Sale44.5039017,35524,449Aug 25 07:08 PM
Pravda RicardoChief Transformation OfficerAug 24 '23Sale44.4737916,85430,224Aug 25 06:37 PM
Hopson RickyPres. Clinical Dev Supply DivAug 24 '23Sale44.5627612,29922,040Aug 25 06:52 PM
Gunther ScottSVP, Quality & Reg. AffairsAug 24 '23Sale44.5726911,98929,932Aug 25 07:12 PM
Carletti LorenzoSVP Global Ops Ph & Cons HlthAug 24 '23Sale44.712169,6578,746Aug 25 06:58 PM
Lickfold CharlesSVP, CIOAug 24 '23Sale44.721908,49711,339Aug 25 06:45 PM
Hawkeswood Thomas WPres. Pharma Prod Delivery DivAug 24 '23Sale44.721476,5747,533Aug 25 06:48 PM
Hunt PatriciaPres. Consumer Health DivAug 24 '23Sale44.771064,74611,289Aug 25 06:39 PM
Arnold JonathanSVP, CCO & Div. Head BioP Del.Aug 24 '23Sale44.87873,90457,399Aug 25 06:56 PM
Fasman Steven LEVP & Chief Admin OfficerAug 01 '23Sale47.051,63777,02660,216Aug 03 04:02 PM
Maselli AlessandroPresident & CEOAug 01 '23Sale47.131,48569,99586,101Aug 03 05:05 PM
Carletti LorenzoSVP Global Ops Ph & Cons HlthAug 01 '23Sale47.7738318,2964,602Aug 03 04:16 PM
Gennadios AristipposGroup Pres. Pharma & ConsumerAug 01 '23Sale47.5928113,37386,488Aug 03 04:21 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Aug 01 '23Sale47.7227613,17117,516Aug 03 04:30 PM
Pravda RicardoChief Transformation OfficerAug 01 '23Sale47.5626912,79319,739Aug 03 05:13 PM
Hawkeswood Thomas WPres. Pharma Prod Delivery DivAug 01 '23Sale47.9725812,3765,106Aug 03 04:41 PM
Hopson RickyPres. Clinical Dev Supply DivAug 01 '23Sale47.861959,33316,257Aug 03 04:47 PM
Gunther ScottSVP, Quality & Reg. AffairsAug 01 '23Sale47.901909,10123,798Aug 03 04:37 PM
Hunt PatriciaPres. Consumer Health DivAug 01 '23Sale47.951617,7209,154Aug 03 04:51 PM
Lickfold CharlesSVP, CIOAug 01 '23Sale47.901356,4665,570Aug 03 05:00 PM
Arnold JonathanSVP, CCO & Div. Head BioP Del.Aug 01 '23Sale47.80622,96455,896Aug 03 04:09 PM